Biotechs Urged to Weigh in as Supreme Court Considers Myriad
"Hoping against hope" the Supreme Court is simply signaling a need to provide greater guidance to the Federal Circuit is one way to view the high court's decision to grant cert in Association for Molecular Pathology v. Myriad Genetics Inc., according to Kevin E. Noonan, a partner in the Chicago office of McDonnell Boehnen Hulbert & Berghoff LLP.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter